

CANCER AUSTRALIA

Entity Resources and Planned Performance



CANCER AUSTRALIA

Section 1: Entity Overview and Resources	286
1.1 Strategic Direction Statement	286
1.2 Entity Resource Statement	287
1.3 Budget Measures	289
Section 2: Outcomes and Planned Performance	290
2.1 Budgeted Expenses and Performance	290
Section 3: Budgeted Financial Statements	295
3.1 Budgeted Financial Statements	295
3.2 Budgeted Financial Statements Tables	296



Section 1: Entity Overview and Resources

1.1 STRATEGIC DIRECTION STATEMENT¹

As the Australian Government’s national cancer control agency, Cancer Australia provides leadership in cancer control across all cancers, with reference to burden of disease, cancer incidence, survival, and mortality. Cancer Australia also has a focus on populations which experience poorer health outcomes, including Aboriginal and Torres Strait Islander peoples and people living in rural and remote Australia.

The Australian Government, through Cancer Australia, aims to: provide national leadership in cancer control to improve cancer outcomes; coordinate evidence-based interventions with a range of health care providers and groups across the continuum of cancer care; lead the development of sustainable and effective models of cancer care; and provide advice on appropriate cancer care. Cancer Australia also oversees a dedicated budget for cancer research and strengthening national data capacity.

In order to minimise the impact of cancer, Cancer Australia will, in 2017-18:

- implement the 2017-18 Budget measure *Invest in Medical Research – fighting childhood cancer*, which will provide \$4.4 million aimed at increasing Australia’s research capacity to advance diagnosis, treatment, management, analysis, and improve data and awareness of childhood cancer, as well as \$1.4 million to fast track international research collaborations of paediatric brain cancer in Australia;
- translate evidence to inform the development and implementation of policies and programs in cancer control;
- promote best practice cancer care to health professionals across Australia including the updating and dissemination of evidence-based information on ovarian cancer;
- lead the development of innovative, sustainable, and evidence-based models of cancer care;
- strengthen national data capacity through reporting on cancer stage and treatment for selected cancers;
- fund research in priority areas, including a focus on low survival cancers common among children (0-14 years of age), through the Priority-driven Collaborative Cancer Research Scheme;
- provide information for people affected by cancer about their diagnosis and treatment; and
- promote cancer awareness to the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the

¹ For more information about the strategic direction of Cancer Australia, refer to the current corporate plan, available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting#corporate

Auditor-General Act 1997, and is a Non-corporate Commonwealth Entity under the Public Governance, Performance and Accountability Act 2013.

1.2 ENTITY RESOURCE STATEMENT

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, please refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (i.e. appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: Cancer Australia Resource Statement – Budget Estimates for 2017-18 as at Budget May 2017

	2016-17 Estimated actual \$'000	2017-18 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	4,749	4,585
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	11,270	11,110
s74 retained revenue receipts ^(b)	1,130	127
Departmental capital budget ^(c)	82	81
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	12,482	11,318
Total departmental resourcing	17,231	15,903
ADMINISTERED		
Prior year appropriation available	30	30
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	17,150	18,679
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	17,150	18,679
Total administered resourcing	17,180	18,709
Total resourcing for Cancer Australia	34,411	34,612
	2016-17	2017-18
Average staffing level (number)	69	69

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2017-18.

^(b) Estimated retained revenue receipts under section 74 of the PGPA Act 2013.

^(c) Departmental Capital Budget (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Refer to Table 3.5 for further details.

^(d) For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2017-18.

1.3 BUDGET MEASURES

Budget measures in Part 1 relating to Cancer Australia are detailed in Budget Paper No. 2 and are summarised below.

Table 1.2: Cancer Australia 2017-18 Budget Measures

	Program	2016-17 \$'000	2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000
Investing in Medical Research - fighting childhood cancer						
Cancer Australia						
Administered expenses	1.1	-	1,307	2,186	2,086	250
Total expenses		-	1,307	2,186	2,086	250

Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which Government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Enhanced Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide an entity's complete performance story.

Cancer Australia's most recent corporate plan is available at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting

Cancer Australia's most recent annual performance statement is available at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting/annual-reports

2.1 BUDGETED EXPENSES AND PERFORMANCE

Outcome 1

Minimised impacts of cancer, including through national leadership in cancer control with targeted research, cancer service development, education and consumer support

Program Contributing to Outcome 1

Program 1.1: Improved Cancer Control

Linked Programs

Other Commonwealth entities that contribute to Outcome 1

Department of Health

Program 2.4: Preventive Health and Chronic Disease Support

The Department of Health has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program and the National Cervical Screening Program.

Budgeted Expenses for Cancer Australia

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses for Cancer Australia

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward Year 1 \$'000	2019-20 Forward Year 2 \$'000	2020-21 Forward Year 3 \$'000
Program 1.1: Improved Cancer Control					
Administered expenses					
Ordinary annual services ^(a)	17,150	18,679	19,802	19,966	18,381
Departmental expenses					
Departmental appropriation ^(b)	12,400	11,237	11,206	11,214	11,269
Expenses not requiring appropriation in the Budget year ^(c)	443	437	457	436	339
Operating deficit (surplus)	-	-	-	-	-
Total for Program 1.1	29,993	30,353	31,465	31,616	29,989
Total expenses for Outcome 1	29,993	30,353	31,465	31,616	29,989
	2016-17	2017-18			
Average staffing level (number)	69	69			

^(a) Appropriation (Bill No. 1) 2017-18.

^(b) Departmental appropriation combines 'Ordinary annual services (Appropriation Bill No. 1)' and 'Revenue from independent sources (s74)'.
^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees.

Movement of Funds

There were no movements of administered funds between years.

Planned Performance for Cancer Australia

Table 2.1.2 below details the performance criteria for the program associated with Outcome 1.² It also summarises how the program is delivered and where 2017-18 Budget measures have materially changed the program.

Table 2.1.2: Performance Criteria for Cancer Australia

Purpose
To minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control.
Outcome 1
Minimised impacts of cancer, including through national leadership in cancer control with targeted research, cancer service development, education and consumer support
Program 1.1: Improved Cancer Control
<p>Cancer Australia is a specialist agency providing national leadership in cancer control across the cancer continuum of care. Cancer Australia guides scientific improvements in cancer prevention, treatment and care; coordinates and liaises between the wide range of groups and health care providers with an interest in cancer; makes recommendations to the Australian Government about cancer policies and priorities; assists with the implementation of policies and programs in cancer control; and oversees a dedicated budget for research into cancer.</p> <p>In 2017-18, the Government will provide \$5.8 million for childhood cancer research, including \$1.4 million for paediatric brain cancer clinical trials and \$4.4 million aimed at increasing Australia's research capacity to advance diagnosis, treatment, management, analysis, and improve data and awareness of childhood cancer.</p>
Delivery
<p>A. Providing leadership in national cancer control and promoting appropriate cancer care</p> <ul style="list-style-type: none"> • Promote evidence-based practice for identified cancers and population groups. • Lead a shared agenda for improvements in cancer outcomes for Aboriginal and Torres Strait Islander peoples in agreed priority areas across the cancer continuum. • Monitor and report national trends in cancer control. <p>B. Funding priority research and strengthening national data capacity</p> <ul style="list-style-type: none"> • Partner with non-government organisations to maximise Government investment in priority areas of cancer research through the Priority-driven Collaborative Cancer Research Scheme. • Provide funding to support the development of industry independent cancer clinical trials. • Report on cancer stage and treatments for selected cancers. <p>C. Promoting cancer awareness and providing information about cancer to the community</p> <ul style="list-style-type: none"> • Engage consumers to inform Cancer Australia's work. • Provide evidence-based cancer information, resources and data for consumers, health professionals and the community through the Cancer Australia websites, including the Children's cancer website, and social media platforms.

² Progress against the performance criteria published in the 2016-17 Portfolio Budget Statements will be reported in the 2016-17 Cancer Australia Annual Report.

Performance criteria				
A. Providing leadership in national cancer control and promoting appropriate cancer care				
Research is translated into evidence-based information, policy and clinical practice.				
2016-17 Estimated result	2017-18 Target	2018-19 (& beyond) Target		
The release of the Cancer Australia Statement – influencing best practice in breast cancer, has been achieved and the Statement is available on the Cancer Australia website. ³	Evidence is advanced about the most appropriate interventions across the continuum of cancer care through the publication of research and guidance in specific cancers.	As per 2017-18.		
B. Funding priority research and strengthening national data capacity				
Minimum number of cancer research grants funded by Cancer Australia through the Priority-driven Collaborative Cancer Research Scheme.				
2016-17 Estimated result	2017-18 Target	2018-19 Target	2019-20 Target	2020-21 Target
Target of 7 is on track to be achieved by 30 June 2017.	7	7	7	7
Percentage of funding for applied research through the Priority-driven Collaborative Cancer Research Scheme.				
2016-17 Estimated result	2017-18 Target	2018-19 Target	2019-20 Target	2020-21 Target
Target of ≥70% is on track to be achieved by 30 June 2017.	≥70%	≥70%	≥70%	≥70%

³ Further information is available at: thestatement.canceraustralia.gov.au/

C. Promoting cancer awareness and providing information about cancer to the community				
Total number of Cancer Australia resources available to inform the community.				
2016-17 Estimated result	2017-18 Target	2018-19 Target	2019-20 Target	2020-21 Target
Target of 280 is on track to be achieved by 30 June 2017.	285	290	290	290
Number of consumers involved in Cancer Australia advisory and project activities.				
2016-17 Estimated result	2017-18 Target	2018-19 Target	2019-20 Target	2020-21 Target
Target of 60 is on track to be achieved by 30 June 2017.	70	70	80	80
Material changes to Program 1.1 resulting from the following measures:				
<ul style="list-style-type: none"> • There are no material changes to Program 1.1 resulting from measures. 				

Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2017-18 Budget year, including the impact of Budget measures and resourcing on financial statements.

3.1 BUDGETED FINANCIAL STATEMENTS

3.1.1 Differences Between Entity Resourcing and Financial Statements

This section is not applicable to Cancer Australia.

3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

Departmental Resources

Comprehensive Income Statement

This statement details budgeted financial results for Cancer Australia in 2017-18.

Cancer Australia anticipates a break even position for the Budget year 2017-18 and all forward years.

Total expenses for 2017-18 are consistent with former years. The income statement deficit in the Budget year 2017-18 and forward years is as a result of depreciation being unfunded.

Balance Sheet

There are no significant movements expected in the assets or liabilities of Cancer Australia.

Cash Flow

Cash flows are consistent with income, expenses and asset movements.

Administered Resources

Administered funding for Cancer Australia programs will continue in 2017-18. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia.

In the 2017-18 Budget, the Government will provide \$5.8 million over four years to improve outcomes for childhood cancer, including \$1.4 million for paediatric brain cancer clinical trials and \$4.4 million aimed at increasing Australia's research capacity to advance diagnosis, treatment, management, analysis, and improve data and awareness of childhood cancer.

3.2 BUDGETED FINANCIAL STATEMENTS TABLES

Table 3.1: Comprehensive Income Statement (showing net cost of services for the period ended 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
EXPENSES					
Employee benefits	8,451	8,559	8,928	8,934	8,987
Supplier expenses	3,145	2,873	2,475	2,474	2,479
Grants expenses	1,000	-	-	-	-
Depreciation and amortisation	247	242	260	242	142
Total expenses	12,843	11,674	11,663	11,650	11,608
LESS:					
OWN-SOURCE INCOME					
Revenue					
Other revenue	1,130	127	129	128	129
Total revenue	1,130	127	129	128	129
Gains					
Other	196	195	197	194	197
Total gains	196	195	197	194	197
Total own-source income	1,326	322	326	322	326
Net cost of (contribution by) services	11,517	11,352	11,337	11,328	11,282
Revenue from Government	11,270	11,110	11,077	11,086	11,140
Surplus (deficit)	(247)	(242)	(260)	(242)	(142)
Surplus (deficit) attributable to the Australian Government	(247)	(242)	(260)	(242)	(142)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(247)	(242)	(260)	(242)	(142)

Note: Reconciliation of comprehensive income attributable to the agency

	2016-17 \$'000	2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000
Total comprehensive income (loss) attributable to the Australian Government	(247)	(242)	(260)	(242)	(142)
plus non-appropriated expenses depreciation and amortisation expenses	247	242	260	242	142
Total comprehensive income (loss) attributable to the agency	-	-	-	-	-

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	214	214	214	214	214
Receivables	4,562	4,512	4,429	4,339	4,337
Total financial assets	4,776	4,726	4,643	4,553	4,551
Non-financial assets					
Buildings	-	-	-	-	-
Property, plant and equipment	414	312	243	188	132
Intangibles	69	60	33	17	17
Other	66	66	66	66	66
Total non-financial assets	549	438	342	271	215
Total assets	5,325	5,164	4,985	4,824	4,766
LIABILITIES					
Payables					
Suppliers	649	649	649	649	649
Other payables	545	545	545	545	545
Total payables	1,194	1,194	1,194	1,194	1,194
Provisions					
Employees	1,834	1,834	1,834	1,834	1,834
Other provisions	180	180	180	180	180
Total provisions	2,014	2,014	2,014	2,014	2,014
Total liabilities	3,208	3,208	3,208	3,208	3,208
Net Assets	2,117	1,956	1,777	1,616	1,558
EQUITY					
Contributed equity	164	245	326	407	491
Reserves	-	-	-	-	-
Retained surpluses (accumulated deficits)	1,953	1,711	1,451	1,209	1,067
Total equity	2,117	1,956	1,777	1,616	1,558

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2017-18)

	Retained earnings \$'000	Asset revaluation reserve \$'000	Contributed equity/capital \$'000	Total equity \$'000
Opening balance as at 1 July 2017				
Balance carried forward from previous period	1,953	-	164	2,117
Surplus (deficit) for the period	(242)	-	-	(242)
Capital budget - Bill 1 (DCB)	-	-	81	81
Other movements	-	-	-	-
Estimated closing balance as at 30 June 2018	1,711	-	245	1,956

DCB = Departmental Capital Budget.

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	11,294	11,020	11,022	11,035	11,002
GST	221	223	238	232	232
Other cash received	1,130	127	129	128	129
Total cash received	12,645	11,370	11,389	11,395	11,363
Cash used					
Employees	8,251	8,559	8,928	8,934	8,988
Suppliers	3,009	2,538	2,140	2,139	2,141
Grants	1,000	-	-	-	-
GST	221	223	238	232	232
Total cash used	12,481	11,320	11,306	11,305	11,361
Net cash from (or used by) operating activities	164	50	83	90	2
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	246	131	164	171	86
Total cash used	246	131	164	171	86
Net cash from (or used by) investing activities	(246)	(131)	(164)	(171)	(86)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	82	81	81	81	84
Total cash received	82	81	81	81	84
Net cash from (or used by) financing activities	82	81	81	81	84
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	214	214	214	214	214
Cash and cash equivalents at the end of the reporting period	214	214	214	214	214

DCB = Departmental Capital Budget.

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	82	81	81	81	84
Total capital appropriations	82	81	81	81	84
Total new capital appropriations represented by:					
Purchase of non-financial assets	82	81	81	81	84
Total represented by	82	81	81	81	84
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	82	81	81	81	84
Funded internally from departmental resources	164	50	83	90	2
Total acquisitions of non-financial assets	246	131	164	171	86
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	246	131	164	171	86
Total cash used to acquire assets	246	131	164	171	86

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budget (DCB).

Table 3.6: Statement of Asset Movements (Budget year 2017-18)

	Buildings	Other property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2017				
Gross book value	-	1,186	582	1,768
Accumulated depreciation/ amortisation and impairment	-	(772)	(513)	(1,285)
Opening net book balance	-	414	69	483
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation ordinary annual services	-	111	20	131
Total additions	-	111	20	131
Other movements				
Depreciation/amortisation expense	-	(213)	(29)	(242)
Total other movements	-	(213)	(29)	(242)
As at 30 June 2018				
Gross book value	-	1,297	602	1,899
Accumulated depreciation/ amortisation and impairment	-	(985)	(542)	(1,527)
Closing net book balance	-	312	60	372

Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants	15,794	16,382	16,737	16,881	17,013
Suppliers	1,356	2,297	3,065	3,085	1,368
Total expenses administered on behalf of Government	17,150	18,679	19,802	19,966	18,381

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	30	30	30	30	30
Receivables	39	39	39	39	39
Other financial assets	387	387	387	387	387
Total financial assets	456	456	456	456	456
Total assets administered on behalf of Government	456	456	456	456	456
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Suppliers	242	242	242	242	242
Grants	60	60	60	60	60
Other payables	154	154	154	154	154
Total payables	456	456	456	456	456
Total liabilities administered on behalf of Government	456	456	456	456	456

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

	2016-17 Estimated actual \$'000	2017-18 Budget \$'000	2018-19 Forward estimate \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
GST	695	707	707	707	707
Total cash received	695	707	707	707	707
Cash used					
Grant payments	15,177	16,382	16,737	16,881	17,013
Suppliers	1,973	2,297	3,065	3,085	1,368
GST	695	707	707	707	707
Total cash used	17,845	19,386	20,509	20,673	19,088
Net cash from (or used by) operating activities	17,150	18,679	19,802	19,966	18,381
Net increase (or decrease) in cash held	17,150	18,679	19,802	19,966	18,381
Cash at beginning of reporting period	30	30	30	30	30
Cash from Official Public Account for:					
- appropriations	17,150	18,679	19,802	19,966	18,381
Cash at end of reporting period	30	30	30	30	30